<DOC>
	<DOCNO>NCT01575483</DOCNO>
	<brief_summary>The purpose post-marketing surveillance investigate confirm type incidence newly identify adverse event factor affect safety efficacy Onglyza® regulatory authority manage marketing approval properly .</brief_summary>
	<brief_title>Korean Post-marketing Surveillance Onglyza®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Female male patient least 18 year age Patients diagnosis T2DM initiate Onglyza® treatment within approved indication Korea Indication approve Onglyza® Korea Patients contraindication use Onglyza® ( clarified Korean label )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>